Sia Daneshmand
Program Director · University of Southern California/Los Angeles General Medical Center
Credentials: · · · ·
History
Research
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
Systematic review or meta-analysis · The Journal of Urology · 2016 · 1,110 citations
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Nature · 2021 · 552 citations
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
Review · European Urology · 2016 · 520 citations
107 papers · 82 as a resident
75 papers
56 papers
- SS
47 papers
45 papers
43 papers
- AG
40 papers · 37 as a resident
35 papers · 18 as a resident
Grants
- 2025–2027
National Cancer Institute · R21
PI · $426.8K · University of Southern California
Clinical trials
- 2023–2028
Principal investigator · Recruiting
University of Southern California
- 2019–2022
Principal investigator · Withdrawn · Phase 3
University of Southern California
- 2016–2019
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
Principal investigator · Completed · Phase 1
Taris Biomedical LLC
- 2015–2027
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma
Principal investigator · Active not recruiting
University of Southern California